CBD medicines available for over-the-counter sale from 2021

Investment Highlights:

  • Althea applauds the final decision by the Therapeutic Goods Administration (TGA) to amend the current Poisons Standard to down schedule cannabidiol (CBD) to allow greater access through a new Schedule 3 entry
  • The amendment will allow Australian patients to purchase CBD products upon consultation with a pharmacist, without the need for a prescription
  • Althea will now proceed with plans to register several CBD products for sale in Schedule 3, including the top selling Althea CBD100

For full announcement – read here